

Can't find or afford Jardiance? Here are real alternatives including other SGLT2 inhibitors and treatment options your doctor may consider in 2026.
Whether it's a stock-out, an insurance issue, or cost concerns, there are times when you simply can't get your hands on Jardiance (Empagliflozin). If that's happening to you, the most important thing is: don't just stop your treatment. There are real alternatives that your doctor can prescribe instead.
Before we get into the options, let's quickly cover what Jardiance does and why it matters — so you can have an informed conversation with your healthcare provider about switching.
Jardiance is the brand name for Empagliflozin, a medication in the SGLT2 inhibitor class. SGLT2 stands for sodium-glucose co-transporter 2 — a protein in your kidneys that normally reabsorbs sugar back into your blood. Jardiance blocks this protein, causing your kidneys to flush excess sugar out through your urine.
This mechanism does several things at once:
For a full explanation, see our article on how Jardiance works.
Farxiga is the closest alternative to Jardiance. It's also an SGLT2 inhibitor and works in the same way — by blocking sugar reabsorption in the kidneys. Farxiga is FDA-approved for:
Farxiga comes in 5 mg and 10 mg tablets taken once daily. Its side effect profile is very similar to Jardiance, including increased risk of genital yeast infections, urinary tract infections, and dehydration. The cash price for Farxiga is comparable to Jardiance, typically ranging from $500 to $600 per month without insurance.
Many doctors consider Farxiga and Jardiance to be interchangeable for most patients, especially for diabetes and heart failure. If your pharmacy doesn't have Jardiance, Farxiga is often the first alternative your prescriber will consider.
Invokana was actually the first SGLT2 inhibitor approved by the FDA (in 2013, one year before Jardiance). It's available in 100 mg and 300 mg tablets taken once daily.
Invokana is FDA-approved for:
One important note: Invokana carries a boxed warning about an increased risk of lower limb amputations, particularly toes and feet. This was observed in clinical trials and is something to discuss with your doctor. The risk is higher in patients with a history of amputation, peripheral vascular disease, or diabetic foot ulcers.
The cash price for Invokana is typically $500 to $650 per month.
Steglatro is another SGLT2 inhibitor, available in 5 mg and 15 mg tablets taken once daily. It's FDA-approved for type 2 diabetes as an adjunct to diet and exercise.
Unlike Jardiance and Farxiga, Steglatro does not have FDA approval for heart failure or chronic kidney disease. It also has less cardiovascular outcome data. However, as an SGLT2 inhibitor, it works through the same mechanism and provides similar blood sugar-lowering effects.
Steglatro may be a reasonable option if your primary need is glycemic control in type 2 diabetes. The cash price is typically $400 to $550 per month, making it slightly more affordable than Jardiance.
Brenzavvy is the newest SGLT2 inhibitor on the market, approved in 2023. It comes as a 20 mg tablet taken once daily for type 2 diabetes. Like Steglatro, it doesn't yet have approvals beyond diabetes, but it works through the same SGLT2 mechanism.
Brenzavvy may be worth asking about if other options aren't available or aren't covered by your insurance.
If you can't take any SGLT2 inhibitor — for example, due to recurring genital infections or kidney function concerns — your doctor might consider other drug classes:
Switching medications is something you should always do under your doctor's guidance. Here's what to keep in mind:
For more on drug interactions with these medications, see our guide on Jardiance drug interactions.
If your heart (or your doctor) is set on Jardiance, don't give up. Use Medfinder to check real-time pharmacy stock, try independent pharmacies, or ask about mail-order options. Read our full guide on how to find Jardiance in stock near you.
Not being able to fill your Jardiance prescription is frustrating, but it's not a dead end. Other SGLT2 inhibitors like Farxiga, Invokana, Steglatro, and Brenzavvy offer similar benefits, and your doctor can help you find the right fit. The key is to act quickly, stay in communication with your healthcare team, and never stop your medication without professional guidance.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.